Gland Pharma Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/js091wffgs3mk5u6xyg6gksf.pdf

Key Takeaways


Cenexi Turnaround: The Quarter's Central Problem

Srinivas Sadu: "We recognize that the acquisition thesis has taken longer than expected to fructify, but our strategy to achieve robust growth and profitability remains centered on high value products."

US Business: Volume Up, Revenue Flat, Margins Protected

Srinivas Sadu: "What happened also was the product, there were several key products where the material costs have gone down and the end market price also was reduced, the transfer price. So, the revenue came down, but the margin was intact."

GLP-1 & Complex Injectables: The Growth Bet


ROW & Other Markets: A Reset Year

Shyamakant Giri: "We internally have reasons to believe that this business can double over the next 3 to 5 years."

Margins & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue growthMid-teens growthFY26
Subsequent years growthLow-20s growthFY27–FY28
US revenue growth18% (12% products, 6% CMO)FY26
Base business EBITDA marginMaintain 37–38%Ongoing
Cenexi breakevenPositive EBITDAQ3 FY26
Cenexi EBITDA marginDouble-digitFY27
Cenexi revenue (with additional capex)€30 crore3 years
Cenexi EBITDA margin (at €30 crore revenue)High teens percentage3 years
Cartridge capacity14 crore units (new 10-crore line installed)End of CY2025
New PFS line (Cenexi)OperationalBeginning of CY2026
Lyophilizer qualification (Braine-l'Alleud)FinalizedEnd of CY2025
Biologics revenue (Dr. Reddy's collaboration)~₹100 croreFY26
New product launches (US)~33 launchesFY26
ROW businessDouble3–5 years

Key Metrics

MetricQ4 FY25
Consolidated revenue₹1,424.9 cr, declined YoY but improved from trailing quarter
Consolidated EBITDA₹347.5 cr, 24% margin, up 100 bps YoY
Consolidated net profit₹186.5 cr, up 3% YoY; PAT margin 13%
Base business (ex-Cenexi) revenue₹1,033.2 cr, 12% YoY decline
Base business EBITDA margin38%, up from 36% in Q4 FY24
Base business gross margin61%, up from 56% in Q4 FY24
Consolidated gross margin66%, up from 61% in Q4 FY24
US market volume growth (FY25)+9% including new launches
US market price change (FY25)-5%
New launches contribution to total revenue (FY25)6% of total revenue
New launches gross margin (FY25)72% vs company average of 58%
ROW market revenue₹240.4 cr, 17% of total revenue, 14% YoY decrease
India market revenue₹52.5 cr, 4% of total revenue
R&D expenditure₹50.3 cr, 4.9% of base business revenue
Cenexi revenue€43 million, affected by lower production at Fontenay facility
Cenexi gross margin79%, improved from 77% in Q3 FY25
Profit share and milestone income~₹145 cr profit share (14% of revenue), milestone 6%
Enoxaparin and Heparin contribution16% of total revenue in Q4 FY25
US new product launches in Q44 new molecules launched
Total cash and cash equivalents₹2,556.2 cr as of March 31, 2025; net cash ₹2,287 cr after Cenexi debt
CAPEX₹88.6 cr in Q4 FY25
Cash conversion cycle172 days for 12 months ending March 2025, vs 173 days prior year
FY26 consolidated revenue growth guidanceMid-teens growth expected
Cenexi positive EBITDA targetQ3 FY26
Cenexi double-digit EBITDA margin targetFY27
Biologics revenue expected in FY26~₹100 cr
US expected growth in FY2618%, 12% from products and 6% from CMO projects